Neurizon Reports No Adverse Events as Final Patient Completes Sclerosis Drug Trial; Shares Fall 4%

MT NewswiresMay 5 00:22 ET

Neurizon Therapeutics Makes Three Executive Appointments; Shares Up 15%

MT NewswiresApr 17 01:25 ET

Neurizon Therapeutics Completes Study of Drug Candidate on Mouse Motor Neuron Cell Line

MT NewswiresApr 4 02:39 ET

Neurizon Finds Positive Results for Lead Drug in 3D Brain Model Study

The Market HeraldMar 31 20:53 ET

ASX Biggest Gainers

MT NewswiresMar 27 22:01 ET

Neurizon Therapeutics Moves to Lift FDA Suspension on NUZ-001 Drug Candidate With Two Studies; Shares Fall 5%

MT NewswiresMar 16 23:30 ET

Investing in Neurizon Therapeutics (ASX:NUZ) Five Years Ago Would Have Delivered You a 54% Gain

Yahoo FinanceFeb 18 15:19 ET

Neurizon Therapeutics Ltd: Appendix 4D - Half-year Financial Report - 31 December 2024

ASXFeb 16 22:28 ET · Announcements

Neurizon Gets US Patent for Cancer Drug Candidate; Shares Up 16%

MT NewswiresFeb 4 23:00 ET

Neurizon Therapeutics Says FDA Places Its Investigational New Drug Application on Hold; Shares Hit New 52-Week Low

MT NewswiresJan 16 20:18 ET

Neurizon's ALS Drug Candidate Receives Orphan Medicinal Product Designation in Europe; Shares Down 3%

MT NewswiresDec 17, 2024 21:41 ET

Neurizon Reports Positive Results From Preclinical Study of Amyotrophic Lateral Sclerosis Treatment Candidate; Shares Fall 4%

MT NewswiresNov 17, 2024 23:34 ET

Neurizon's Fast-track Application for Flagship Drug in Europe Received 'Positively'

The Market HeraldNov 10, 2024 18:54 ET

PharmAust Changes Name to Neurizon Therapeutics

MT NewswiresOct 15, 2024 00:42 ET